Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Down syndrome and Alzheimer's

Topic: Brain proteins, microglia and lab models

Plain-language summary

Down Syndrome (DS) is the most common genetic form of intellectual disability that leads in the majority of cases to development of early-onset Alzheimer-like dementia (AD). The neuropathology of DS has several common features with AD including alteration of redox homeostasis, mitochondrial deficits, and inflammation among others. Interestingly, some of the genes encoded by chromosome 21 are responsible of increased oxidative stress (OS) conditions that are further exacerbated by decreased antioxidant defense. Previous studies from our groups showed that accumulation of oxidative damage is an early event in DS neurodegeneration and that oxidative modifications of selected proteins affects the integrity of the protein degradative systems, antioxidant response, neuronal integrity and energy metabolism. In particular, the current review elaborates recent findings demonstrating the accumulation of oxidative damage in DS and we focus attention on specific deregulation of iron metabolism, which affects both the central nervous system and the periphery. Iron dysmetabolism is a well-recognized factor that contributes to neurodegeneration; thus we opine that better understanding how and to what extent the concerted loss of iron dyshomeostasis and increased OS occur in DS could provide novel insights for the development of therapeutic strategies for the treatment of Alzheimer-like dementia.

What this study adds

Evidence grade: Low

This is a narrative review. This review discusses oxidative damage and disturbed iron metabolism in Down syndrome as possible contributors to early-onset Alzheimer-like dementia, and suggests this understanding could inform future therapeutic strategies. No treatment is tested, so no therapy is established.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Barone, E., Arena, A., Head, E., Butterfield, D. A., & Perluigi, M. (2018). Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism. Free radical biology & medicine. https://doi.org/10.1016/j.freeradbiomed.2017.07.009

Vancouver

Barone E, Arena A, Head E, Butterfield DA, Perluigi M. Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism. Free radical biology & medicine. 2018. doi:10.1016/j.freeradbiomed.2017.07.009. PMID: 28705658.

BibTeX

@article{barone2018-28705658,
  author  = {Barone, E. and Arena, A. and Head, E. and Butterfield, D. A. and Perluigi, M.},
  title   = {{Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism}},
  journal = {Free radical biology \& medicine},
  year    = {2018},
  doi     = {10.1016/j.freeradbiomed.2017.07.009},
  pmid    = {28705658},
  url     = {https://doi.org/10.1016/j.freeradbiomed.2017.07.009}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review discusses oxidative damage and disturbed iron metabolism in Down syndrome as possible contributors to early-onset Alzheimer-like dementia, and suggests this understanding could inform future therapeutic strategies. No treatment is tested, so no therapy is established.

Study details

How this study scored 42/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 42 of 100.42 of 100 points earned58 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Free radical biology & medicine)
Journal's citation record 3 / 4 Free Radical Biology and Medicine: journal h-index 378 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2018 — within 10 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 54 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 5.4 citations a year over 10 year(s) since 2018
Impact for its field and year 3 / 6 Cited 3.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 2 other studies in this library
Still being cited 2 / 4 Cited 15 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Marzia Perluigi: h-index 63 (OpenAlex, whole career)
Institution's track record 1 / 3 Sapienza University of Rome: institution h-index 1,145 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 3 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 28705658)
Free to read 0 / 2 Behind a paywall — scores zero
Total 42 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 19.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Down syndrome and Alzheimer's from nearby years

Also tagged “down”

527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Down syndrome and Alzheimer's

See all studies in Down syndrome and Alzheimer's →